Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
View abstract on PubMed
Summary
This summary is machine-generated.An early invasive strategy, combined with tirofiban, significantly reduced major cardiac events in patients with unstable angina and myocardial infarction without ST-segment elevation. This approach proved superior to conservative management for improving patient outcomes.
Area Of Science
- Cardiology
- Interventional Cardiology
- Acute Coronary Syndromes
Background
- Ongoing debate exists regarding the optimal management strategy for unstable angina and myocardial infarction without ST-segment elevation.
- Comparing early invasive versus conservative approaches is crucial for improving patient outcomes.
Purpose Of The Study
- To evaluate the efficacy of an early invasive strategy compared to a conservative strategy in patients with unstable angina and myocardial infarction without ST-segment elevation.
- To assess the impact of routine catheterization and revascularization versus selective intervention on major cardiac events.
Main Methods
- 2220 patients with unstable angina/myocardial infarction without ST-segment elevation were enrolled.
- Patients received aspirin, heparin, and tirofiban, then randomized to early invasive (catheterization within 4-48 hours) or conservative (selective catheterization) strategies.
- The primary endpoint was a composite of death, nonfatal myocardial infarction, and rehospitalization for acute coronary syndrome at six months.
Main Results
- The early invasive strategy resulted in a significantly lower rate of the primary endpoint (15.9% vs. 19.4%, P=0.025) at six months.
- Death or nonfatal myocardial infarction rates were also reduced in the early invasive group (7.3% vs. 9.5%, P<0.05).
- The odds ratio for the primary endpoint favored the early invasive strategy (0.78; 95% CI, 0.62 to 0.97).
Conclusions
- An early invasive strategy, when combined with tirofiban, significantly decreases major cardiac events in patients with unstable angina and myocardial infarction without ST-segment elevation.
- These findings support the use of early invasive management in conjunction with glycoprotein IIb/IIIa inhibition for this patient population.
- The study highlights the benefit of proactive intervention in managing high-risk acute coronary syndromes.